HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Colon Cancer.
Study finds link between industry payments to oncologists and non-recommended cancer treatments
Patients with cancer whose oncologist receives payments from industry appear more likely to receive some non-recommended and low value treatments, finds a US study published